| 1 |
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer |
Ovarian Neoplasm Epithelial|Ovarian Cancer|Fallopian Tube Neoplasms|Peritoneal Carcinoma|Ovarian Serous Adenocarcinoma |
Biological: Oregovomab|Drug: Paclitaxel|Drug: Carboplatin|Biological: Placebo |
CanariaBio Inc.|Raptim Research Pvt. Ltd |
Phase 2 |
NCT05605535 |
2023-02-07 |
| 2 |
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B |
Hemophilia A|Hemophilia B |
Drug: marstacimab |
Pfizer |
Phase 3 |
NCT05611801 |
2022-12-09 |
| 3 |
Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease |
COVID-19 |
Biological: Asunercept|Other: Placebo |
Apogenix AG |
Phase 3 |
NCT05639192 |
2022-11-03 |
| 4 |
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow |
SGA, Turner Syndrome, Noonan Syndrome, ISS |
Drug: Somapacitan|Drug: Norditropin® |
Novo Nordisk A/S |
Phase 3 |
NCT05330325 |
2022-08-10 |
| 5 |
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome |
Sjogren Syndrome |
Biological: VAY736|Other: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05349214 |
2022-08-04 |
| 6 |
Recombinant Follicle-stimulating Hormone in Treatment for Infertility |
Female Infertility |
Drug: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen |
Bharat Serums and Vaccines Limited |
Phase 3 |
NCT05266924 |
2022-07-23 |
| 7 |
To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects |
Healthy |
Biological: ADL-018|Biological: US-licensed XOLAIR|Biological: EU-Approved XOLAIR |
Kashiv BioSciences, LLC |
Phase 1 |
NCT05413161 |
2022-07-07 |
| 8 |
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study |
Systemic Lupus Erythematosus |
Biological: Daxdilimab |
Horizon Therapeutics Ireland DAC|Horizon Pharma Ireland, Ltd., Dublin Ireland |
Phase 2 |
NCT05430854 |
2022-06-01 |
| 9 |
Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers |
COVID-19 Respiratory Infection |
Biological: BBV154(Intranasal) & covaxin |
Bharat Biotech International Limited |
Phase 3 |
NCT05522335 |
2022-04-16 |
| 10 |
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors |
Haemophilia A With or Without Inhibitors |
Drug: Mim8 |
Novo Nordisk A/S |
Phase 3 |
NCT05306418 |
2022-04-04 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.